This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

This study has been terminated.
Information provided by:
Wellstat Therapeutics Identifier:
First received: September 4, 2002
Last updated: June 23, 2005
Last verified: May 2005
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.

Condition Intervention Phase
Solid Tumors Drug: triacetyluridine Drug: fluorouracil Drug: leucovorin Drug: camptosar Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.

Resource links provided by NLM:

Further study details as provided by Wellstat Therapeutics:

Primary Outcome Measures:
  • Safety and Maximum Tolerated Dose

Estimated Enrollment: 24
Study Start Date: August 2002
Estimated Study Completion Date: March 2004

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Must be at least 18 years of age;
  • Life expectancy: At least 3 months;
  • Performance status: ECOG of 0 or 1;
  • Histologic or cytologic proof of a solid tumor cancer that is not amenable to curative surgical resection;
  • Evaluable or measurable disease documented within 4 weeks of the start of treatment;
  • Prior chemotherapy or radiotherapy is allowed if 4 weeks or more have elapsed prior to starting treatment and patients have recovered from toxicities of prior treatment;
  • Adequate organ function:

Hematopoietic: ANC = 1500/ul or more, Platelets = 100,000/ul or more, Hemoglobin = 9.5 g/dL or more, transfusion prior to evaluation is allowed; Hepatic: Bilirubin = 2.0 mg/dL or less and SGPT(ALT) and SGOT(AST) < 3 x upper limit of normal (< 5 x upper limit of normal if liver metastases present) Renal: Serum Creatinine < 2.0 mg/dL;

  • Patient has the initiative, geographic proximity, and means to be compliant with the protocol;
  • Fertile patients (male or female) must agree to use effective contraception;
  • Must be able to swallow and retain tablets.

Exclusion Criteria

  • Major surgery within the four weeks preceding the start of treatment;
  • Serious medical or psychiatric illness that would prevent self-determined informed consent;
  • Intensive chemotherapy treatment;
  • Infection or antibiotics at the time of screening;
  • Uncontrolled cardiovascular, pulmonary, renal, neurologic, psychiatric, or hepatic dysfunction;
  • Pregnant or nursing;
  • Pre-existing diarrhea or uncontrolled clinically significant illness other than cancer (i.e. ulcerative colitis, malabsorption syndrome);
  • Brain metastases that have not been stable for more than 3 months;
  • Known Dihydropyrimidine Dehydrogenase (DPD) deficiency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00044785

United States, Maryland
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Wellstat Therapeutics
  More Information Identifier: NCT00044785     History of Changes
Other Study ID Numbers: 401.02.001
Study First Received: September 4, 2002
Last Updated: June 23, 2005

Keywords provided by Wellstat Therapeutics:
colorectal cancer
gastric cancer
breast cancer

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors processed this record on August 21, 2017